Physician profile
Kristi Sutton
NPI 1720202989
$1,646.61
in general payments reported to CMS, 2019-2025
24 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $69.89 · 2021: $45.73 · 2022: $284 · 2023: $499 · 2024: $398 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.67 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $174.87 | 2019-2025 | |
| Novo Nordisk INC | $154.23 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Otsuka America Pharmaceutical, INC. | $124.51 | 2023-2024 | Rexulti |
| Amgen INC. | $120.03 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $112.53 | 2022-2024 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $106.74 | 2022-2024 | Nexletol, Contrave, Nexlizet |
| Astellas Pharma US INC | $94.46 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $91.77 | 2023-2025 | Gemtesa |
| Abbvie INC. | $90.78 | 2022-2025 | Qulipta |
| Glaxosmithkline, LLC. | $80.42 | 2023-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $68.98 | 2020-2024 | Mounjaro |
| Lundbeck LLC | $63.17 | 2023-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $60.24 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.93 | 2024 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $47.45 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.94 | 2019-2020 | |
| Esperion Therapeutics, INC. | $36.13 | 2021-2022 | |
| Eisai INC. | $33.66 | 2024 | |
| Merck Sharp & Dohme LLC | $18.82 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.56 | 2023 | Xifaxan, Trulance |
| Corium, LLC | $14.83 | 2023 | Adlarity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.